SymBio Pharmaceuticals Ltd
TSE:4582
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
88
209
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
SymBio Pharmaceuticals Ltd
Free Cash Flow
SymBio Pharmaceuticals Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SymBio Pharmaceuticals Ltd
TSE:4582
|
Free Cash Flow
-ÂĄ4.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
-17%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Free Cash Flow
ÂĄ922.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
13%
|
CAGR 10-Years
24%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Free Cash Flow
-ÂĄ68.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Free Cash Flow
ÂĄ269.3B
|
CAGR 3-Years
71%
|
CAGR 5-Years
21%
|
CAGR 10-Years
1%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Free Cash Flow
ÂĄ348.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Astellas Pharma Inc
TSE:4503
|
Free Cash Flow
ÂĄ334.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
18%
|
CAGR 10-Years
12%
|
|
SymBio Pharmaceuticals Ltd
Glance View
SymBio Pharmaceuticals Ltd. engages in the pharmaceutical business. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 141 full-time employees. The company went IPO on 2011-10-20. Along with medicine specialists, contract research organizations (CROs) and other pharmaceutical companies, the Company is engaged in the design and operation of clinical tests, the manufacture and sale of new drugs specializing in three therapeutic areas: cancer, blood diseases and autoimmune diseases. The firm develops new medicines using chemical compounds proofed by preclinical tests and clinical tests. The firm manufactures and sells medicines through domestic and foreign pharmaceutical companies. The firm's pipelines include anticancer drugs, such as SyB L-0501, SyB L-1101 and SyB C-1101.
See Also
What is SymBio Pharmaceuticals Ltd's Free Cash Flow?
Free Cash Flow
-4.8B
JPY
Based on the financial report for Sep 30, 2025, SymBio Pharmaceuticals Ltd's Free Cash Flow amounts to -4.8B JPY.
What is SymBio Pharmaceuticals Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-17%
Over the last year, the Free Cash Flow growth was -255%.